# Cancer Drug and Biological Products - Clinical Data in Marketing Applications - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/cancer-drug-and-biological-products-clinical-data-in-marketing-applications/46d12435-8972-4d63-a8eb-3c3d753c0178

> FDA guidance document: Cancer Drug and Biological Products - Clinical Data in Marketing Applications. Issue date: October 11, 2001. Get complete insights and analysis.

---

## Details

- Title: Cancer Drug and Biological Products - Clinical Data in Marketing Applications
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2001-10-11
- Last Changed: 2020-04-30
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2000-D-0100">FDA-2000-D-0100</a>

## Related Documents

- [M4S: The CTD -- Safety Appendices](https://www.globalkeysolutions.net/guidances/guidance-document/m4s-the-ctd-safety-appendices/21e0b200-6c21-43a7-a559-c1fb8a1ec89a)
- [IND Meetings for Human Drugs and Biologics Chemistry, Manufacturing, and Controls Information:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/ind-meetings-for-human-drugs-and-biologics-chemistry-manufacturing-and-controls-information-guidance-for-industry/d36eac77-5bcf-4737-b484-0bdcaf6b5c77)
- [IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/ind-exemptions-for-studies-of-lawfully-marketed-drug-or-biological-products-for-the-treatment-of-cancer-guidance-for-industry/fa85146f-e37f-41a7-a38d-60e7f38b337d)